Development and validation of the NEOS2 score for prediction of long-term outcomes and improvement after first-line immunotherapy in patients with anti-NMDAR encephalitis: an international cohort study.

Brenner J, Bastiaansen AEM, Guasp M, Muñiz-Castrillo S, Iizuka T, de Bruijn MAAM, Muñoz-Lopetegi A, Martínez-Hernández E, Picard G, Vogrig A, Millot M, Finke C, Geis C, Lewerenz J, Melzer N, Prüss H, Räuber S, Ringelstein M, Rostàsy K, Sühs KW, Thaler FS, Wandinger KP, Wurdack K, Crijnen YS, Kerstens J, van Steenhoven RW, Veenbergen S, Schreurs MWJ, van den Berg R, Volovici V, Neuteboom RF, de Vries JM, Sillevis Smitt PAE, Nagtzaam MMP, Franken SC, GENERATE Study Group, Dalmau J, Leypoldt F, Honnorat J, Titulaer MJ

Open source

DOI
10.1016/j.lanepe.2025.101562
Published
2026 Mar
Container
The Lancet regional health. Europe
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.lanepe.2025.101562,
  title = {Development and validation of the NEOS2 score for prediction of long-term outcomes and improvement after first-line immunotherapy in patients with anti-NMDAR encephalitis: an international cohort study.},
  author = {Brenner J and Bastiaansen AEM and Guasp M and Muñiz-Castrillo S and Iizuka T and de Bruijn MAAM and Muñoz-Lopetegi A and Martínez-Hernández E and Picard G and Vogrig A and Millot M and Finke C and Geis C and Lewerenz J and Melzer N and Prüss H and Räuber S and Ringelstein M and Rostàsy K and Sühs KW and Thaler FS and Wandinger KP and Wurdack K and Crijnen YS and Kerstens J and van Steenhoven RW and Veenbergen S and Schreurs MWJ and van den Berg R and Volovici V and Neuteboom RF and de Vries JM and Sillevis Smitt PAE and Nagtzaam MMP and Franken SC and GENERATE Study Group and Dalmau J and Leypoldt F and Honnorat J and Titulaer MJ},
  year = {2026},
  journal = {The Lancet regional health. Europe},
  doi = {10.1016/j.lanepe.2025.101562},
  url = {https://doi.org/10.1016/j.lanepe.2025.101562}
}

RIS

TY  - JOUR
TI  - Development and validation of the NEOS2 score for prediction of long-term outcomes and improvement after first-line immunotherapy in patients with anti-NMDAR encephalitis: an international cohort study.
AU  - Brenner J
AU  - Bastiaansen AEM
AU  - Guasp M
AU  - Muñiz-Castrillo S
AU  - Iizuka T
AU  - de Bruijn MAAM
AU  - Muñoz-Lopetegi A
AU  - Martínez-Hernández E
AU  - Picard G
AU  - Vogrig A
AU  - Millot M
AU  - Finke C
AU  - Geis C
AU  - Lewerenz J
AU  - Melzer N
AU  - Prüss H
AU  - Räuber S
AU  - Ringelstein M
AU  - Rostàsy K
AU  - Sühs KW
AU  - Thaler FS
AU  - Wandinger KP
AU  - Wurdack K
AU  - Crijnen YS
AU  - Kerstens J
AU  - van Steenhoven RW
AU  - Veenbergen S
AU  - Schreurs MWJ
AU  - van den Berg R
AU  - Volovici V
AU  - Neuteboom RF
AU  - de Vries JM
AU  - Sillevis Smitt PAE
AU  - Nagtzaam MMP
AU  - Franken SC
AU  - GENERATE Study Group
AU  - Dalmau J
AU  - Leypoldt F
AU  - Honnorat J
AU  - Titulaer MJ
PY  - 2026
JO  - The Lancet regional health. Europe
DO  - 10.1016/j.lanepe.2025.101562
UR  - https://doi.org/10.1016/j.lanepe.2025.101562
ER  -

APA

J, B., AEM, B., M, G., S, M., T, I., MAAM, D. B., A, M., E, M., G, P., A, V., M, M., C, F., C, G., J, L., N, M., H, P., S, R., M, R., K, R., KW, S., FS, T., KP, W., K, W., YS, C., J, K., RW, V. S., S, V., MWJ, S., R, V. D. B., V, V., RF, N., JM, D. V., PAE, S. S., MMP, N., SC, F., Group, G. S., J, D., F, L., J, H., & MJ, T. (2026). Development and validation of the NEOS2 score for prediction of long-term outcomes and improvement after first-line immunotherapy in patients with anti-NMDAR encephalitis: an international cohort study.. The Lancet regional health. Europe. https://doi.org/10.1016/j.lanepe.2025.101562

Source records